Your browser doesn't support javascript.
loading
Mapping oncogenic protein interactions for precision medicine.
Sharifi Tabar, Mehdi; Francis, Habib; Yeo, Dannel; Bailey, Charles G; Rasko, John E J.
Afiliación
  • Sharifi Tabar M; Gene & Stem Cell Therapy Program Centenary Institute, The University of Sydney, Camperdown, New South Wales, Australia.
  • Francis H; Cancer & Gene Regulation Laboratory Centenary Institute, The University of Sydney, Camperdown, New South Wales, Australia.
  • Yeo D; Faculty of Medicine & Health, The University of Sydney, Sydney, New South Wales, Australia.
  • Bailey CG; Gene & Stem Cell Therapy Program Centenary Institute, The University of Sydney, Camperdown, New South Wales, Australia.
  • Rasko JEJ; Cancer & Gene Regulation Laboratory Centenary Institute, The University of Sydney, Camperdown, New South Wales, Australia.
Int J Cancer ; 151(1): 7-19, 2022 07 01.
Article en En | MEDLINE | ID: mdl-35113472
Normal protein-protein interactions (normPPIs) occur with high fidelity to regulate almost every physiological process. In cancer, this highly organised and precisely regulated network is disrupted, hijacked or reprogrammed resulting in oncogenic protein-protein interactions (oncoPPIs). OncoPPIs, which can result from genomic alterations, are a hallmark of many types of cancers. Recent technological advances in the field of mass spectrometry (MS)-based interactomics, structural biology and drug discovery have prompted scientists to identify and characterise oncoPPIs. Disruption of oncoPPI interfaces has become a major focus of drug discovery programs and has resulted in the use of PPI-specific drugs clinically. However, due to several technical hurdles, studies to build a reference oncoPPI map for various cancer types have not been undertaken. Therefore, there is an urgent need for experimental workflows to overcome the existing challenges in studying oncoPPIs in various cancers and to build comprehensive reference maps. Here, we discuss the important hurdles for characterising oncoPPIs and propose a three-phase multidisciplinary workflow to identify and characterise oncoPPIs. Systematic identification of cancer-type-specific oncogenic interactions will spur new opportunities for PPI-focused drug discovery projects and precision medicine.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Medicina de Precisión / Neoplasias Límite: Humans Idioma: En Revista: Int J Cancer Año: 2022 Tipo del documento: Article País de afiliación: Australia Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Medicina de Precisión / Neoplasias Límite: Humans Idioma: En Revista: Int J Cancer Año: 2022 Tipo del documento: Article País de afiliación: Australia Pais de publicación: Estados Unidos